Ling Shi Huang

7112439, Sep 26, 2006

Jan 8, 2004

10/753309

Leslie Sydnor Johnson - Darnestown MD, US
Ling Huang - Gaithersburg MD, US

MacroGenics, Inc. - Rockville MD

C12N 5/16
C12N 15/85
C12N 1/21

435328, 4353201, 4352523

The present invention provides a dual expression vector, and methods for its use, for the expression and secretion of a full-length polypeptide of interest in eukaryotic cells, and a soluble domain or fragment of the polypeptide in bacteria. When expressed in bacteria, transcription from a bacterial promoter within a first intron and termination at the stop codon in a second intron results in expression of a fragment of the polypeptide, e. g. , a Fab fragment, whereas in mammalian cells, splicing removes the bacterial regulatory sequences located in the two introns and generates the mammalian signal sequence, allowing expression of the full-length polypeptide, e. g. , IgG heavy or light chain polypeptide. The dual expression vector system of the invention can be used to select and screen for new monoclonal antibodies, as well as to optimize monoclonal antibodies for binding to antigenic molecules of interest.

7351803, Apr 1, 2008

May 29, 2003

10/449566

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Gaithersburg MD, US
Hua Li - North Potomac MD, US
Nadine Tuaillon - Sykesville MD, US

Macrogenics, Inc. - Rockville MD

C07K 16/00
C12P 21/08
C07K 17/00

5303871, 5303873, 5303881, 53038822

CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-CD16A antibodies, optionally lacking effector function, are used for treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.

7355008, Apr 8, 2008

Jan 9, 2004

10/754922

Jeffrey Stavenhagen - Brookville MD, US
Sujata Vijh - Gaithersburg MD, US
Christopher Rankin - Clarksburg MD, US
Sergey Gorlatov - Gaithersburg MD, US
Ling Huang - Gaithersburg MD, US

Macrogenics, Inc. - Rockville MD

C07K 16/00
C12P 21/08
C07K 1/00

5303871, 5303873, 5303877

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

7521542, Apr 21, 2009

May 10, 2005

11/126978

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Gaithersburg MD, US

MacroGenics, Inc. - Rockville MD

C12P 21/08
C07K 16/00
A61K 39/395
G01N 33/574
G01N 33/53
C12P 21/04
C07H 21/04

53038822, 5303873, 5303881, 5303888, 5303917, 4241331, 4241411, 4241431, 4241551, 4241831, 435 723, 435 793, 435 696, 435 7021

The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

7572456, Aug 11, 2009

Sep 13, 2005

11/226886

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Bethesda MD, US

MacroGenics, Inc. - Rockville MD

A61K 39/00
A61K 39/12
A61Q 5/00
C12P 7/24
C12P 7/52
C12N 5/16
C12N 11/10

4242181, 424 702, 4241331, 4241391, 435141, 435147, 435178, 435345

The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.

7618628, Nov 17, 2009

Jun 4, 2007

11/757932

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Bethesda MD, US
Hua Li - North Potomac MD, US
Nadine Tuaillon - Sykesville MD, US

Macrogenics Inc. - Rockville MD

A61K 39/395
C07K 16/00

4241301, 5303871

CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.

7786270, Aug 31, 2010

May 25, 2007

11/754015

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Bethesda MD, US

MacroGenics, Inc. - Rockville MD

C12P 21/08

5303873, 530350, 5303871

The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

7838635, Nov 23, 2010

Jun 4, 2007

11/757939

Leslie S. Johnson - Darnestown MD, US
Ling Huang - Bethesda MD, US
Hua Li - North Potomac MD, US
Nadine Tuaillon - Sykesville MD, US

MacroGenics, Inc. - Rockville MD

C07K 16/00
C12P 21/08
C07K 14/00
C12N 15/00

5303871, 5303873, 5303881, 53038822

CD16A binding proteins useful for the reduction of a deleterious immune response are described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia.